New Report "World Market for Biosimilars and the Potential for US Follow-on Biologics" available through Aarkstore Enterprise

The information and analysis presented in this report are based on an extensive survey of senior management in the biogeneric drug industry.

Online PR News – 24-September-2009 – – Biosimilars, or generic biologic drugs, are marketed around the world but still restricted in the U.S. This may soon change, has released this timely study of the market in Europe and other areas in the world and the possibility of a U.S. Market in the near future. As part of its research, this report provides the following


Current market size and forecasts for biogenerics in Europe and Rest of World Markets

Review of Marketed Biological Drugs with Expired Patents

Review of Marketed Biological Drugs with Active Patents

Profiles of the Major Competitors in biogenerics

Discussion of FDA and EMEA regulatory activity

Pending U.S. Legislation and Projections for US Markets

Coverage of Patent Trends, Pricing Trends, Healthcare Spending, IP and ohter Relevant Issues and Trends

For purposes of study has focused on the market for products which have lost patent in key markets. Projections were made based on the progress that is occurring within the generic arena in terms of capabilities, capital, interest, and development of biopharmaceuticals.

Kalorama has identified the biopharmaceuticals that have lost patent protection and are likely to be the first products that will be attempted by generic companies. Some of these products are relatively simple in structure (by biotech complexity) such as the insulins and human growth hormones, while others are extremely difficult to process.

There are a number of biopharmaceuticals that are identified as potential targets for generic development. Many of these biopharmaceutical patents have expired. Many of these products sport manufacturer sales of over $10 billion, presenting a ripe opportunity for generic manufacturers. However, because many of these products demonstrate sales of over $1 billion per year, it is anticipated that there will considerable resistance from the biotech innovator companies in allowing generic capitalization and consequently approvals.

The information and analysis presented in this report are based on an extensive survey of senior management in the biogeneric drug industry. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals.

Key information from published literature was used to conduct interviews with over 42 industry executives and product managers to validate and obtain expert opinion on current and future trends in the psychotherapeutic industry. Interviews were also used to confirm and/or adjust market size, as well as in formulating market projections.

All market data pertains to the world market at the manufacturers’ level. Data are expressed in current U.S. dollars. The geographic scope of the study is worldwide with particular emphasis on the United States and Europe.

For more information, please visit :
Or email us at or call +919272852585

visit our website